Sartorius (SRT) AI Stock Analysis

0 Followers

Sartorius

(BX Swiss:SRT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring Consumables DemandStrong recurring consumables growth supports revenue visibility because customers repurchase products as biopharmaceutical batches run and production scales. This installed-process exposure can deepen customer retention and provide a durable base that is less dependent on individual equipment orders.

Negative Factors

Meaningful LeverageLeverage has improved but remains material, limiting financial flexibility relative to a lower-debt position. A sustained debt burden can constrain capital allocation and make the company more sensitive to weaker margins, slower demand, or the need to fund strategic investments.

Sartorius (SRT) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 15.56B
Dividend Yield: ―
Average Volume (3M): 52
Price to Earnings (P/E): 72.5
Beta (1Y): 0.17
Revenue Growth: ―
EPS Growth: ―
Country: Switzerland
Employees: 14,042
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Sartorius Business Overview & Revenue Model

Company Description

Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection...

Sartorius Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:7.98%|Next Earnings Date:Feb 23, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. Management reported broad-based sales growth, continued recovery in equipment and non-recurring business, expanding margins, substantially higher free cash flow, lower leverage, and upgraded LPS guidance. The main challenges were tariff-related growth headwinds, pull-forward and timing effects in LPS, ATS project delays, difficult Q4 comparisons, FX pressure, and continued cyclicality in equipment demand. These lowlights were acknowledged but did not outweigh the operational, financial, and balance-sheet improvements.

Positive Updates

Solid Group Growth and Improved Profitability

Sartorius reported solid first-nine-month 2026 results, with both divisions contributing to growth. Underlying EBITDA increased 6.9% to EUR 828 million, and the underlying EBITDA margin expanded by 50 basis points to 30.2%, driven mainly by higher volumes and operating leverage.

Negative Updates

U.S. Academia and Government Activity Remains Below Prior Levels

Management said U.S. academia and government performance had improved slightly but was not at the levels seen in prior years.

Company Guidance

The company confirmed full-year operational sales growth broadly around the midpoint of the 5%-9% range for the group, 6%-10% for Bioprocess Solutions, and around the upper end of the 2%-6% range for Lab Products & Services; including customer compensation for tariff surcharges, growth in constant currencies is expected to be in the lower half of the respective guidance ranges for the group and BPS, and around the upper end of the range for LPS. Underlying EBITDA margin is expected to be slightly above 30% for the group, slightly above 32% for Bioprocess Solutions, and slightly above 21% for LPS. The full-year CapEx ratio expectation was lowered from around 12.5% to around 12%, net debt to underlying EBITDA remains expected at slightly above three times at year-end, MatTek’s contribution remains approximately 30 basis points for the group and 1.5 percentage points for LPS, tariff refund applications were approximately EUR 40 million with around EUR 31 million received by the end of September and the outstanding EUR 9 million expected by year-end, and FX is modeled as a headwind of slightly more than one percentage point on reported revenue growth for the full year and a tailwind of slightly below two percentage points in Q4. For Sartorius Stedim Biotech, operational growth is expected around the midpoint of the 6%-10% range, reported growth in constant currencies including customer compensation is expected to be in the lower half of this range, underlying EBITDA margin is expected to be slightly above 31%, the full-year CapEx ratio expectation was lowered from around 13.3% to around 13%, net debt to underlying EBITDA remains expected at slightly above two times at year-end, and FX headwind should be approximately 1.2 percentage points on reported revenue growth for the full year and a tailwind of approximately 1.7 percentage points in Q4.

Sartorius Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

CH:SRT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:G1A	80Outperform	EUR 11.67B	26.99	17.46%	1.78%	5.37%	9.46%
DE:EVK	64Neutral	EUR 9.68B	55.36	2.16%	4.77%	1.98%	83.13%
DE:SBS	61Neutral	EUR 303.90M	-653.75	-0.17%	2.29%	―	―
DE:PFV	59Neutral	EUR 1.59B	23.55	12.29%	4.52%	0.35%	116.73%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:GXI	52Neutral	EUR 1.08B	-2.75	-32.84%	0.13%	8.90%	-609.05%

* General Sector Average

Performance Comparison

CH:SRT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:SRT	Sartorius (0NIQ)	210.91	40.94	24.09%
DE:EVK	Evonik Industries AG	20.96	7.70	58.07%
DE:G1A	GEA Group AG	73.15	15.45	26.77%
DE:GXI	Gerresheimer AG	31.92	7.06	28.40%
DE:PFV	Pfeiffer Vacuum Technology	162.00	12.69	8.50%
DE:SBS	STRATEC Biomedical	26.15	5.61	27.31%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sartorius AI Stock Analysis